Previous 10 |
Lizhi (LIZI) +29%.Ekso Bionics Holdings (EKSO) +25%.AgEagle Aerial Systems (UAVS) +22%.ENGlobal Corporation (ENG) +23%.Supernus Pharmaceuticals (SUPN) +23%.Scopus BioPharma (SCPS) +21%.Mogo (MOGO) +18%.Magnite (MGNI) +18%.Kopin Corporation (KOPN) +18%.Magna International (MGA) +18%.InMed Phar...
Gainers: [[MGNI]] +15.1%. [[SCPS]] +11.4%. [[OCN]] +10.5%. [[CLNE]] +6.9%. [[AMTX]] +4.7%.Losers: [[VYGR]] -11.9%. [[YCBD]] -11.4%. [[SPPI]] -9.4%. [[AHT]] -9.0%. [[ABCL]] -8.7%. For further details see: MGNI, SCPS, YCBD and SPPI among after-hours movers
Gainers: Anterix (ATEX) +67%.NantKwest (NK) +55%.500.com Limited (WBAI) +51%.Editas Medicine (EDIT) +47%.EyeGate Pharmaceuticals (EYEG) +45%.Organovo Holdings (ONVO) +36%.Nuverra Environmental Solutions (NES) +33%.RealPage (RP) +29%.Agios Pharmaceuticals (AGIO) +29%.CuriosityStream (CURI...
Gainers: EyeGate Pharmaceuticals (EYEG) +78%, Editas Medicine (EDIT) +42%, NantKwest (NK) +30%, Liminal BioSciences (LMNL) +29%, Agios Pharmaceuticals (AGIO) +24%.Losers: Scopus BioPharma (SCPS) -17%, uniQure (QURE) -16%, C...
News, Short Squeeze, Breakout and More Instantly...
Scopus BioPharma Inc. Company Name:
SCPS Stock Symbol:
NASDAQ Market:
Scopus BioPharma Inc. Website:
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet Bi...